keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer, NSCLC, SCLC

keyword
https://www.readbyqxmd.com/read/29753578/racial-ethnic-disparities-in-end-of-life-care-quality-among-lung-cancer-patients-a-seer-medicare-based-study
#1
Siddharth Karanth, Suja S Rajan, Gulshan Sharma, Jose-Miguel Yamal, Robert O Morgan
INTRODUCTION: Cancer end-of-life care and associated racial-ethnic disparities have been in focus during the last few years due to concerns regarding subjective care variations and poor quality of care. Given the high mortality rate and disease burden of lung cancer, end-of-life care quality is particularly crucial for this disease. This study uses previously validated measures and examines racial-ethnic disparities in lung cancer end-of-life care quality. METHODS: This study involves retrospective analysis of patients ≥66 years, who were diagnosed with stage I-IV lung cancer, and who died on or before December 31, 2013, using the Surveillance Epidemiology and End Result-Medicare data from 1991-2013...
May 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29748024/expression-of-brain-derived-neurotrophic-factor-and-its-receptor-trkb-is-associated-with-poor-prognosis-and-a-malignant-phenotype-in-small-cell-lung-cancer
#2
Shinichi Kimura, Taishi Harada, Kayo Ijichi, Kentaro Tanaka, Renpeng Liu, Daisuke Shibahara, Yuko Kawano, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto
OBJECTIVES: TrkB is a receptor for brain-derived neurotrophic factor (BDNF) and is highly expressed in various cancers, with BDNF-TrkB signaling having been implicated in tumor progression and metastasis. The role of the BDNF-TrkB system in small cell lung cancer (SCLC), a neuroendocrine cancer, has remained unclear, however. We examined BDNF and TrkB expression in SCLC patients as well as the function of BDNF-TrkB signaling in SCLC cell lines. MATERIALS AND METHODS: BDNF and TrkB expression in tumor specimens of 58 SCLC patients and 20 non-small cell lung cancer (NSCLC) patients was examined by immunohistochemistry and was scored on the basis of the distribution and intensity of staining...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29731983/exosomal-mirnas-species-in-the-blood-of-small-cell-and-non-small-cell-lung-cancer-patients
#3
Valeriy Poroyko, Tamara Mirzapoiazova, Arin Nam, Isa Mambetsariev, Bolot Mambetsariev, Xiwei Wu, Aliya Husain, Everett E Vokes, Deric L Wheeler, Ravi Salgia
Lung cancer is a devastating disease with overall bleak prognosis. Current methods to diagnose lung cancer are rather invasive and are inadequate to detect the disease at an early stage when treatment is likely to be most effective. In this study, a shotgun sequencing approach was used to study the microRNA (miRNA) cargo of serum-derived exosomes of small cell lung cancer (SCLC) (n=9) and non-small cell lung cancer (NSCLC) (n=11) patients, and healthy controls (n=10). The study has identified 17 miRNA species that are differentially expressed in cancer patients and control subjects...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29729229/triple-test-with-tumor-markers-cyfra-21-1-he4-and-progrp-might-contribute-to-diagnosis-and-subtyping-of-lung-cancer
#4
Elif Tugce Korkmaz, Deniz Koksal, Funda Aksu, Z Gunnur Dikmen, Duygu Icen, Emin Maden, Sevgen Onder, Filiz Akbiyik, Salih Emri
BACKGROUND AND AIM: Early diagnosis and histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed patients with LC. METHODS: Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and 30 patients with benign lung disease. Progastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21...
May 2, 2018: Clinical Biochemistry
https://www.readbyqxmd.com/read/29692625/histological-subtype-of-lung-cancer-affects-acceptance-of-illness-severity-of-pain-and-quality-of-life
#5
Jacek Polański, Mariusz Chabowski, Beata Jankowska-Polańska, Dariusz Janczak, Joanna Rosińczuk
Introduction: Histologic classification of lung cancer plays an important role in clinical practice. Two main histological subtype of lung cancer: small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC) differ in terms of invasiveness, response to treatment, and risk factors, among others. Aims: To evaluate differences in acceptance of illness, level of perceived pain, and quality of life (QoL) between patients with SCLC and NSCLC. Materials and methods: Two hundred and fifty-seven lung cancer patients, who were treated in 2015, completed Acceptance of Illness Scale, Visual Analog Scale for pain, and European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire and European Organization for Research and Treatment of Cancer 13-item Lung Cancer specific Quality of Life Questionnaire...
2018: Journal of Pain Research
https://www.readbyqxmd.com/read/29676470/role-of-mirnas-in-lung-cancer
#6
REVIEW
Arif Uddin, Supriyo Chakraborty
Lung cancer (LC) is the leading cause of cancer-related deaths all over the world, among both men and women, with an incidence of over 200,000 new cases per year coupled with a very high mortality rate. LC comprises of two major clinicopathological categories: small-cell (SCLC) and nonsmall-cell lung carcinoma (NSCLC). The microRNAs (miRNAs) are small noncoding RNAs, usually 18-25 nucleotides long, which repress protein translation through binding to complementary target mRNAs. The miRNAs regulate many biological processes including cell cycle regulation, cellular growth, proliferation, differentiation, apoptosis, metabolism, neuronal patterning, and aging...
April 20, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29675281/coexistent-non-small-cell-carcinoma-and-small-cell-carcinoma-in-a-patient-presenting-with-hyponatremia
#7
Mitchell D Ross, Sreeja Biswas Roy, Pradnya D Patil, Jasmine L Huang, Nitika Thawani, Ralph Drosten, Tanmay S Panchabhai
Despite recent advances in screening methods, lung cancer remains the leading cause of cancer-related deaths worldwide. By the time lung cancer becomes symptomatic and patients seek treatment, it is often too advanced for curative measures. Low-dose computed tomography (CT) screening has been shown to reduce mortality in patients at high risk of lung cancer. We present a 66-year-old man with a 50-pack-year smoking history who had a right upper lobe (RUL) pulmonary nodule and left lower lobe (LLL) consolidation on a screening CT...
2018: Case Reports in Pulmonology
https://www.readbyqxmd.com/read/29669530/small-cell-and-non-small-cell-lung-cancer-form-metastasis-on-cellular-4d-lung-model
#8
Dhruva K Mishra, Ross A Miller, Kristi A Pence, Min P Kim
BACKGROUND: Metastasis is the main cause of death for lung cancer patients. The ex vivo 4D acellular lung model has been shown to mimic this metastatic process. However, the main concern is the model's lack of cellular components of the tumor's microenvironment. In this study, we aim to determine if the intact lung microenvironment will still allow lung cancer metastasis to form. METHODS: We harvested a heart-lung block from a rat and placed it in a bioreactor after cannulating the pulmonary artery, trachea and tying the right main bronchus for 10-15 days without any tumor cells as a control group or with NSCLC (A549, H1299 or H460), SCLC (H69, H446 or SHP77) or breast cancer cell lines (MCF7 or MDAMB231) through the trachea...
April 18, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29650278/circulating-tumor-cells-count-as-a-predictor-of-survival-in-lung-cancer
#9
REVIEW
Konstantinos Syrigos, Oraianthi Fiste, Andriani Charpidou, Dimitra Grapsa
The presence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients was first described in the second half of the 19th century, but research interest in their potential clinical utility has intensified and greatly expanded only in recent years. Herein, we summarize and critically discuss current knowledge on CTC count as a predictor of survival in lung cancer, and comment on the existing challenges and future perspectives in this field. The majority of data published to date, including the results of almost all large cohorts, are strongly supportive of the value of CTC enumeration as a predictor of survival, mainly in advanced/metastatic non-small and small cell lung cancer (NSCLC and SCLC, respectively)...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29627316/kmt2d-mutation-is-associated-with-poor-prognosis-in-non-small-cell-lung-cancer
#10
Fatemeh Ardeshir-Larijani, Priyanka Bhateja, Mary Beth Lipka, Neelesh Sharma, Pingfu Fu, Afshin Dowlati
BACKGROUND: Mixed-lineage leukemia protein 2 (MLL2 or KMT2D) is a histone methyltransferase whose mutation has been associated with a poor prognosis in cancer. We compared the characteristics and significance of KMT2D alterations in non-small-cell lung cancer (NSCLC) with those in small cell lung cancer (SCLC). PATIENTS AND METHODS: Tumors from 194 NSCLC patients with locally advanced or advanced disease and 64 SCLC patients underwent targeted-exome sequencing. The association of KMT2D mutation with overall survival (OS) and progression-free survival (PFS) was measured using Kaplan-Meier methods and further evaluated using multivariable Cox proportional hazards regression model adjusting for known clinical prognostic features...
March 16, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29608934/transition-points-for-the-routine-integration-of-palliative-care-in-patients-with-advanced-cancer
#11
Anna Collins, Vijaya Sundararajan, Jodie Burchell, Jeremy Millar, Sue-Anne McLachlan, Meinir Krishnasamy, Brian H Le, Linda Mileshkin, Peter Hudson, Jennifer Philip
CONTEXT: Increasing emphases are being placed upon early integration of palliative care for patients with advanced cancers, yet barriers to implementation in clinical practice remain. Criteria to standardise referral have been endorsed, but their application are yet to be tested at the population level. OBJECTIVES: This study sought to: 1) establish the need for standardised referral by examining current end of life care outcomes of decedents with cancer; and 2) define transition points within a cancer illness course which are associated with poor prognosis, whereby palliative care should be routinely introduced to augment clinician- based decision making...
March 30, 2018: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29593891/immune-checkpoint-inhibitors-in-small-cell-lung-cancer
#12
REVIEW
Suchita Pakkala, Taofeek K Owonikoko
Small cell lung cancer (SCLC) is a rapidly progressive cancer that often debilitates patients within months of detection and quickly becomes refractory to the limited options of therapy. While SCLC is not generally considered an immunogenic tumor, clinical experience suggests that patients with robust immune response manifesting as paraneoplastic syndrome are more likely to present with limited stage of the disease and tend to have a better prognosis. Monoclonal antibodies targeting critical negative regulators of immune response, so called immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) have expanded the application of immune-based therapies to increasing number of advanced stage cancers...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29593885/high-profile-studies-frequently-and-repetitively-present-data-on-the-same-patients-particularly-in-immunotherapy-studies
#13
Tim Ellis-Caleo, Aaron Lisberg, D Andrew Tucker, Edward B Garon
Background: Traditionally, study results have been presented as abstracts at major scientific meetings at the conclusion of the analysis. Recently, presentations of studies in progress and updates to previously presented data have been allowed at major meetings. The frequency and implications of a single study being presented multiple times, particularly in high profile oral presentations, have not been fully evaluated. Methods: To identify studies presented multiple times, abstracts from an approximately 1-year period from international conferences for three major societies devoted largely or in part to lung cancer research were assessed (ASCO 2015, World Lung 2015, ESMO 2015 and ASCO 2016)...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29587918/-individualized-comprehensive-therapy-for-the-lung-cancer-patients-with-hiv-infection
#14
Lin Wang, Yanzheng Song
BACKGROUND: To observe clinical features, clinical stagings, types ofpathology, treatment options and clinical effects of patients suffer from HIV infection combined with lung cancer, and also to provide guidance for individualized comprehensive treatment of HIV combined with lung cancer. METHODS: Through the retrospective analysis of 53 cases of HIV merger of lung cancer patients admitted in our department, 47 cases of non-small cell lung cancer (NSCLC), 6 cases of small cell lung cancer (SCLC), 24 cases accepted surgery combined chemotherapy, 22 patients with simple chemotherapy, 7 cases give up treatment; 28 cases are in stages I-III, 25 cases are in stage IV; 24 patients received combined chemotherapy in 28 patients with stages I-III, 2 cases gave up treatment, 2 cases with severe chronic obstructive pulmonary disease (COPD) could not tolerate chemotherapy plus surgery...
April 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29533606/drug-combination-synergy-in-worm-like-polymeric-micelles-improves-treatment-outcome-for-small-cell-and-non-small-cell-lung-cancer
#15
Xiaomeng Wan, Yuanzeng Min, Herdis Bludau, Andrew Keith, Sergei S Sheiko, Rainer Jordan, Andrew Z Wang, Marina Sokolsky-Papkov, Alexander V Kabanov
Nanoparticle-based systems for concurrent delivery of multiple drugs can improve outcomes of cancer treatments, but face challenges because of differential solubility and fairly low threshold for incorporation of many drugs. Here we demonstrate that this approach can be used to greatly improve the treatment outcomes of etoposide (ETO) and platinum drug combination ("EP/PE") therapy that is the backbone for treatment of prevalent and deadly small cell lung cancer (SCLC). A polymeric micelle system based on amphiphilic block copolymer poly(2-oxazoline)s (POx) poly(2-methyl-2-oxazoline- block-2-butyl-2-oxazoline- block-2-methyl-2-oxazoline) (P(MeOx- b-BuOx- b-MeOx) is used along with an alkylated cisplatin prodrug to enable co-formulation of EP/PE in a single high-capacity vehicle...
March 27, 2018: ACS Nano
https://www.readbyqxmd.com/read/29523765/targeting-creb-pathway-suppresses-small-cell-lung-cancer
#16
Yifeng Xia, Cheng Zhan, Mingxiang Feng, Mathias Leblanc, Eugene Ke, Narayana Yeddula, Inder M Verma
Small cell lung cancer (SCLC) is the most deadly subtype of lung cancer due to its dismal prognosis. We have developed a lentiviral vector-mediated SCLC mouse model and have explored the role of both the NF-κB and CREB families of transcription factors in this model. Surprisingly, induction of NF-κB activity, which promotes tumor progression in many cancer types including non-small cell lung carcinoma (NSCLC), is dispensable in SCLC. Instead, suppression of NF-κB activity in SCLC tumors moderately accelerated tumor development...
May 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29486777/weak-sharing-of-genetic-association-signals-in-three-lung-cancer-subtypes-evidence-at-the-snp-gene-regulation-and-pathway-levels
#17
Timothy D O'Brien, Peilin Jia, Neil E Caporaso, Maria Teresa Landi, Zhongming Zhao
BACKGROUND: There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC has many subtypes, but the two most common are lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). These subtypes are mainly classified by physiological and pathological characteristics, although there is increasing evidence of genetic and molecular differences as well. Although some work has been done at the somatic level to explore the genetic and biological differences among subtypes, little work has been done that interrogates these differences at the germline level to characterize the unique and shared susceptibility genes for each subtype...
February 27, 2018: Genome Medicine
https://www.readbyqxmd.com/read/29461911/small-cell-lung-cancer-transformation-from-egfr-mutated-lung-adenocarcinoma-a-case-report-and-literatures-review
#18
Yangyang Liu
Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved the response of non-small cell lung cancer (NSCLC) with EGFR-mutant patients. However, these patients inevitably come cross acquired resistance to EGFR-TKIs. The transformation of lung adenocarcinoma to small cell lung cancer (SCLC) following treatment with EGFR-TKIs is rare, which leads to resistance to EGFR-TKIs. The present case concerns a case of a 38-year-old man presenting with cough and dyspnea. Radical resection was performed and confirmed an EGFR exon 21 L858R lung adenocarcinoma...
June 3, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29454048/new-insights-into-the-molecular-characteristics-of-pulmonary-carcinoids-and-large-cell-neuroendocrine-carcinomas-and-the-impact-on-their-clinical-management
#19
REVIEW
Jules L Derks, Noémie Leblay, Sylvie Lantuejoul, Anne-Marie C Dingemans, Ernst-Jan M Speel, Lynnette Fernandez-Cuesta
Carcinoids and large cell neuroendocrine carcinomas (LCNECs) are rare neuroendocrine lung tumors. Here we provide an overview of the most updated data on the molecular characteristics of these diseases. Recent genomic studies showed that carcinoids generally contain a low mutational burden and few recurrently mutated genes. Most of the reported mutations occur in chromatin-remodeling genes (e.g., menin 1 gene [MEN1]), and few affect genes of the phosphoinositide 3-kinase (PI3K)-AKT-mechanistic target of rapamycin gene pathway...
February 14, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29435973/inhibition-of-experimental-small-cell-and-non-small-cell-lung-cancers-by-novel-antagonists-of-growth-hormone-releasing-hormone
#20
Haibo Wang, Xianyang Zhang, Irving Vidaurre, Renzhi Cai, Wei Sha, Andrew V Schally
We investigated the effects of novel antagonists of growth hormone releasing hormone (GHRH)-MIA602 and MIA690-on three human small cell lung cancer (SCLC) lines (H446, DMS53 and H69) and two non-SCLC (NSCLC) lines (HCC827 and H460). In vitro exposure of cancer cells to these GHRH antagonists significantly inhibited cell viability, increased cell apoptosis, decrease cellular levels of cAMP and reduced cell migration. In vivo, the antagonists strongly inhibited tumor growth in xenografted nude mice models. Subcutaneous administration of MIA602 at the dose of 5 μg/day for 4-8 weeks reduced the growth of HCC827, H460 and H446 tumors by 69...
June 1, 2018: International Journal of Cancer. Journal International du Cancer
keyword
keyword
13192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"